Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 2068 word(s) 2068 2021-06-02 08:08:30 |
2 format correct + 318 word(s) 2386 2021-06-04 09:33:34 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Sanchez-Cordero, S. GERD after Bariatric Surgery. Encyclopedia. Available online: https://encyclopedia.pub/entry/10502 (accessed on 29 March 2024).
Sanchez-Cordero S. GERD after Bariatric Surgery. Encyclopedia. Available at: https://encyclopedia.pub/entry/10502. Accessed March 29, 2024.
Sanchez-Cordero, Sergio. "GERD after Bariatric Surgery" Encyclopedia, https://encyclopedia.pub/entry/10502 (accessed March 29, 2024).
Sanchez-Cordero, S. (2021, June 04). GERD after Bariatric Surgery. In Encyclopedia. https://encyclopedia.pub/entry/10502
Sanchez-Cordero, Sergio. "GERD after Bariatric Surgery." Encyclopedia. Web. 04 June, 2021.
GERD after Bariatric Surgery
Edit

Bariatric surgery remains the gold standard treatment for morbidly obese patients. Roux-en-y gastric bypass and laparoscopic sleeve gastrectomy are the most frequently performed surgeries worldwide. Obesity has also been related to gastroesophageal reflux disease (GERD). The management of a preoperative diagnosis of GERD, with/without hiatal hernia before bariatric surgery, is mandatory. Endoscopy can show abnormal findings that might influence the final type of surgery.

gastroesophageal reflux disease endoscopy bariatric surgery sleeve gastrectomy gastric bypass hiatal hernia obesity GERD

1. Introduction

Bariatric surgery (BS) is the most effective treatment for morbid obesity and obtains the best long-term outcomes [1]. Bariatric surgery is also the only treatment option that achieves sustained weight loss and has a positive impact on related co-morbidities [2]. Gastroesophageal reflux disease (GERD) is recognized as a linked condition to obesity, especially morbid obesity [1][3][4]. This association between obesity and GERD is very well-known. In comparison to the general population, obese patients have 2–2.5 more chances of developing reflux symptoms [5][6]. More than 50% of obese patients develop GERD symptoms, and the condition is found in up to 70% of morbidly obese patients who seek bariatric surgery [7][8]. GERD is a common condition with a prevalence of 9% to 25% in Europe [9] and it is increasing in Eastern and Western countries [3]. Part of the problem with GERD is that sometimes we cannot find a correlation between self-reported reflux symptoms and their correlation with objectified reflux, meaning that a high percentage of patients with severe GERD symptoms do not have true pathological GERD on objective testing.
Laparoscopic sleeve gastrectomy (LSG) is currently the most performed surgery worldwide, followed by laparoscopic Roux-en-Y gastric bypass (LRYGB) [10][11]. Laparoscopic sleeve gastrectomy (LSG) seems to achieve equal weight loss as laparoscopic Roux-en-Y bypass (LRYGB), but there is still much debate about other aspects, including metabolic co-morbidity results, long term weight loss, and the quality of life after LSG, mainly concerning the association with gastroesophageal reflux [2]. Mid and long-term follow-up of GERD after bariatric surgery is controversial, however, data suggest that some procedures, such as LSG, could have more severe endoscopic findings compared to clinical symptoms [8]. There is no clear data regarding the correlation between GERD and endoscopic findings, however, some recent reports suggest that there is a need for endoscopic follow-up after LSG to avoid potential serious complications. The aim of this review article is to evaluate the relevant endoscopic findings in patients with GERD symptoms after LRYGB and LSG. Additionally, this review aims to elucidate the appearance of GERD in patients after LSG and LRYGB, and the endoscopic findings and correlations with clinical symptoms.

2. GERD after Bariatric Surgery

There is a vast amount of controversy regarding the symptoms of GERD and their correlation with previous bariatric surgery, and the anatomical situation of the esophageal hiatus. Studies concerning the analysis of the initial anatomical situation of an obese patient, which occurs whenever a LRYGB or LSG is performed, are extremely limited. In fact, there is little evidence that allows us to promote any single technique according to the hiatus situation. It seems that when large hiatal hernias are present in an obese patient in the preoperative setting, LRYGB is the most reasonable surgery [12]. However, some authors have developed protocols to include large hiatoplasties with mesh placement, and even antireflux surgical strategies, while performing LSG.
As we can see in Table 1, sometimes there is a lack of clear correlation between self-reported reflux symptoms and endoscopic findings [13]; bariatric surgery caused either de novo GERD or the aggravation of existing GERD. Gu et al. [14] found the improvement or remission of GERD (40.4%) in LSG and (74.2%) in LRYGB patients. LRYGB had a better effect on GERD (OR = 0.19, 95% CI: 0.12–0.30, p < 0.001) compared to LSG, especially within 3 years and > 3 years [14]. 3534 patients were included, 1918 were subjected to LSG and 1616 to LRYGB, the appearance of new GERD was 9.3% and 2.3% after LSG and LRYGB, respectively (179 in LSG and 37 in LRYGB). In the global analysis, the authors found that LSG showed a higher risk of GERD than LRYGB (OR = 5.10, 95% CI 3.60–7.23, p < 0.001); the results were consistent in the subgroup analysis according to type of study, follow-up time, low heterogeneity, and the risk of GERD after surgery.
Table 1. RYGB-Roux en Y gastric bypass, SG-Sleeve Gastrectomy, Pts—patients; yrs—years; mo—months; Endoscopic findings were graded according to the Los Angeles Classification, Barrett’s esophagus was biopsy proven. NA: not applicable.
Study Journal/Year Number of Patients Age
(Years)
Gender
(Female)
Interval Time from Surgery to Endoscopy Endoscopic Findings (Pts) [%] Weight Loss Results at Evaluation Additional Comments
Borbély et al. [15] SOARD 2018 47
(100%RYGB)
36.5
(19–67)
27
(57.4%)
3.8 yrs (3–12) Esophagitis (C and D LA) (5) [10.6%]
Barrett’s esophagus (7) [14.9%]
Marginal ulcers (4) [8.5%]
30.3 (20.3–47.2) Esophagitis
improved in 19 patients (41.3%), remained similar in 14 (30.4%), and worsened in 13 (28.3%).
Boerlage et al. [16] SOARD 2020 98
(100%RYGB)
41
(±10.0)
223 (89.2%) 7 Mo (2–16) Reflux esophagitis (6) [2.4%]
Marginal ulcer (46) [18.4%]
Stomal stenosis (26) [10.4%]
Bleeding (7) [2.8%]
Candida esophagitis (3) [1.2%]
Food impaction (2) [0.8%]
TWL% 25.7
(±12.9)
 
Huang et al. [17] Gastrointestinal endoscopy
2003
49
(100%RYGB)
46 y (28–65) 42
(85.7%)
49 Mo Marginal ulcer (13) [27%]
Stomal stenosis (9) [19%]
Esophagitis (2) [0.4%]
   
Signorini et al. [18] Surgical endoscopy
2019
227
RYGB 80 (35.2%)
SG 147 (64.8%)
44.9 (36–53) 179 (78.9%) 2 yrs HH de novo
SG group (20) [46%]
RYGB group (1) [2%]
HH+EE postoperative
SG group (16) [11%]
RYGB group (8) [10%]
NA SG had more de novo EE than GBP (25% vs. 5%, p = 0.001).
EE improved in 10%, was resolved in 31.2%,
worsened in 2.5% and remained unchanged in 10% of RYGB
cases.
Lihu Gu et al. [14] Obesity Surgery 2019 23 studies **
LSG 2463
(49.2%)
RGYB 2537
(51.3%)
NA NA NA Correlation of endoscopic findings and GERD symptoms. NA LSG was associated with a higher risk of GERD than LRYGB (odds ratio [OR] = 5.10 [3.60–7.23], p < 0.001).
Dimbezel et al. [19] Obesity Surgery 2020 48
100% LSG
49.63
(±11.69)
42
(87.5%)
62.4 mo Esophagitis (A and B LA) (17) [35.4%]
Esophagitis (C and D LA) (1) [0.2%]
Barrett’s esophagus (4) [8.3%]
40 ± 1.89 kg/m2 RYGB conversion improved EE (14) [29.2%].
Felsenreich et al. [20] Obeisty Sugery 2017 53
100% LSG
38.4 (±12.4) 42 (79%) 129 mo Hiatal hernia de novo (9) [16.9%] Columnar lined esophagus (10) [5.3%] (symptomatic reflux, 7; no reflux, 3). Barrett’s esophagus (3) [15%]   CLE is significantly longer in patients who suffer from symptomatic reflux (4.0 mm) than in patients who do not (2.3 mm) (p = 0.013). RYGBP conversion due to reflux (8) [14%]
Braghetto et al. [21] Arq Bras Cir Dig 2021 39
100% LSG
43.7 (±8.5) 34 5.6 (±2.5 yrs) Erosive esophagitis (33) [84.6%] Esophagitis (A and B LA) (28) [71.7%] Esophagitis (C LA) (5) [12.8%] Barrett’s esophagus (5) [12.8%] 38.4 + 13.4 kg/m2 mean time of appearance of reflux symptoms after surgery was 26.8 + 24.1 mo.
** Systematic review and meta-analysis include 23 studies: 6 RCTs, 6 prospective observational studies, and 11 retrospective observational studies.
LSG is known to have long-term complications related to GERD when compared to LRYGB [19]. The appearance of GERD and its evolution after LSG or LRYGB is related to the drawbacks of these two types of bariatric surgeries. The signs of improvement in GERD following LSG include: the acceleration of gastric emptying [22], a decrease in intra-abdominal pressure associated with the weight loss, and a decrease in acid production with the resection of the stomach [1]. However, the worsening of GERD following LSG includes predominantly the dissection of the gastroesophageal junction [1], the decrement of the lower esophageal sphincter pressure [23], and the modification of the anatomy at the angle of Hiss (responsible for the immediate postoperative GERD) [24].
Some authors defend a routine endoscopy prior to bariatric surgery. Moulla, Y. et al. [25] published a study where the incidence of upper-GI pathologies detected prior to bariatric surgery was evaluated. They reported a total of 636 obese patients with a median BMI (body mass index) reaching super-obesity (Mean BMI: 49 kg/m2 [range 31–92]). Endoscopy detected pathological conditions, such as Helicobacter pylori (Hp) gastritis, in more than 20% of endoscopies, and gastric or duodenal polyps in 6.8%. They also described peptic ulcers in 3.5% of the patients. Reflux esophagitis could be detected in 21.9%. Barrett’s esophagus (BE) was histologically diagnosed in 15.0%, while BE was suspected endoscopically in only 11.3%. Esophageal adenocarcinomas were detected in 0.5%. However, these endoscopic and pathological findings only changed the operative strategy in 1.6% (10 patients) [26]. In agreement with the other authors, they concluded that preoperative upper-GI endoscopy identifies a wide range of abnormal endoscopic findings in obese patients, which may have a significant impact on decision-making, so it should be considered in all obese patients before a bariatric procedure [25]. Unfortunately, the influence of preoperative gastroesophageal reflux disease cannot always be evaluated due to the lack of routine preoperative upper endoscopy, especially in LRYGB [20][26].
On the other hand, Saarinen T. et al. analyzed the clinically significant findings in preoperative endoscopy and how they associate with preexisting GERD symptoms and premalignant lesions. They included 1474 operations, of which 71.0% were RYGB and 27.6% were LSG. They reviewed 86.5% preoperative endoscopic reports, finding that 50.7% were normal and 23.0% had a clinically significant finding, relevant for LSG (HH, esophagitis, BE, esophageal dysplasia). In the same analysis, for patients undergoing LRYGB, only 1.6% of the patients had significant findings relevant for LRYGB (peptic ulcer, atrophic gastritis, gastrointestinal stromal tumor, GIST) and 3.2% of the patients with LSG were converted to LRYGB, due to GERD [27]. These data show that preoperative endoscopy is indicated before LSG, but could be avoided in asymptomatic patients for LRYGB without the risk of gastric pathology.
During the follow-up, upper gastrointestinal symptoms are often difficult to interpret after LSG and LRYGB [16]. Abdominal pain is an especially common symptom after bariatric surgery and endoscopic exploration is commonly used to discard any type of potential complication. However, most common complications can cause gastrointestinal symptoms, such as gallstone disease, marginal ulcer, internal herniation, and stomal stenosis in LRYGB. Stenotic sleeves can also lead to abdominal symptoms, including GERD, nausea, and vomiting [28][29][30]. Complementary explorations need to be performed, such as an upper gastrointestinal X-Ray and upper endoscopy. With these imaging tests, we aim to understand what could produce complications. There is a lack of evidence and clinical data to help us understand which patients will benefit more from an upper endoscopy, because of the high number of upper endoscopies without relevant findings.
Tai et al. [3] show that GERD with morbid obesity and LRYGB substantially improves not only the reflux symptoms but also the erosive esophagitis. Csendes et al. [4] concluded that LRYGB is effective to control pathological gastroesophageal reflux in patients with morbid obesity and Biter et al. [2] demonstrated in a randomized controlled trial that patients who underwent LSG have significantly higher GerdQ scores at both 2 and 12 months, postoperatively, than patients who underwent LRYGB.
An abnormal upper gastrointestinal endoscopy series and dysphagia as a reason for GERD for referral were associated with stomal stenosis in LRYGB [9][31] and margin ulcer [30] after LRYGB. Marginal ulcer incidence has been described as ranging from 0.1% to 4.6% after LRYGB [32]. It is most prevalent in the first year after surgery, but not restricted to the first year, with a mean time between surgery and the first symptoms of approximately 4 months [33]. Stomal stenosis has reported a prevalence ranging from 3.1% to 7.8% [34]. Some of these patients might refer to GERD symptoms, however, it is infrequent to find clear esophagitis in LRYGB patients complaining of upper gastrointestinal symptoms [29][30].
In contrast to the situation following LSG, Gastroesophageal reflux after sleeve gastrectomy is mainly due to the progressive dilatation of cardia, or the presence of a hiatal hernia for an extended period after surgery. It is, however, very relevant and important to notice that asymptomatic patients might have very abnormal endoscopic findings, including esophagitis grades B or C, or even Barrett’s esophagus [35]. The lack of clinical correlation between endoscopy findings and patient symptoms, especially after LSG, have been recently described in the long-term follow-up after laparoscopic sleeve gastrectomy [36]. Genco et al. first demonstrated that almost 17.2% of 110 patients undergoing LSG will develop Barrett’s esophagus (BE) at a median follow-up superior to 55 months. Interestingly, the authors also reported that 26.4% of patients with Barrett’s had no GERD symptoms. This preliminary finding was also confirmed by Soricelli et al. reporting that 21% of patients with evidence of BE had no symptoms of GERD. [37] Felsenreich et al. [20] also reported a high prevalence of BE in 15% of the patients, 10 years after SG, associated with 45% of esophagitis, while only 37% of patients complained of GERD symptoms. From these data, we can extract that the need for systematic endoscopic control beyond 5 years after LSG is independent to the presence of GERD symptoms. More recently, the ASMBS position statement on the rationale for the performance of upper gastrointestinal endoscopy, before and after metabolic and bariatric surgery, stated that a clinical evaluation by symptoms alone does not reliably diagnose or rule out GERD, and that patients with conclusive and objective evidence of preoperative GERD are better served by current techniques of RYGB, rather than SG [38]. Both the expert panel and the current available literature recommend an endoscopy screening of all patients with gastrointestinal symptoms, including GERD symptoms. Therefore, it would be reasonable to perform an endoscopy on patients 3 years after SG, irrespective of GERD symptoms, to rule out Barrett’s esophagus [38].
Another debate is the correlation between symptoms and time after surgery. Shorter time between LRYGB or LSG and the onset of symptoms can lead to technical aspects, such as stenosis of the anastomosis or a kinking of the LSG, which causes an abnormal functioning of the sleeve, along with nausea, vomiting, and GERD [39].
In a recent meta-analysis, in which GERD symptoms were evaluated after bariatric surgery, LSG was converted to LRYGB for patients suffering from severe GERD [14]. The conversion rate was approximately 1.82–8.91% [14]. RYGB is an antireflux procedure because the new anatomy avoids bile reflux, and the small lesser curvature in the gastric pouch excludes the acid-secreting gastric fundus dramatically. It should be stressed that a conversional RYGB due to GERD from a SG should be done with a short gastric pouch.
The conversion from LSG to LRYGB to treat severe GERD after LSG (with or without relevant endoscopic findings) requires complementary studies to detect anatomical defects, such as hiatal hernia de novo [20][31][40][41]. As the effect of a RYGB conversion on the evolution of Barrett’s mucosa is still unclear, endoscopic surveillance should be wisely performed in this setting. Bariatric surgery can improve GERD symptoms; however, new data need to emerge in the next few years, especially to avoid the lack of correlation between endoscopy and symptoms.

3. Conclusions

Endoscopic findings after bariatric surgery are controversial and might have a bad correlation with clinical symptoms. It seems that GERD outcomes for patients with previous GERD or de novo symptoms, are better in patients after being operated by LRYGB, than by LSG. There is a need to study in more depth the meaning of these GERD events, both in the preoperative period and after any bariatric procedure. Multifactorial reasons appear to be related to GERD. In order to avoid severe complications in the mid-long term, such as the appearance of the worsening of GERD, we should recommend LRYGB conversions. Endoscopy should also be recommended after bariatric surgery when clinical symptoms are present and after 3 years of a SG, even without symptoms, in order to diagnose Barret’s esophagus.

References

  1. Picot, J.; Jones, J.; Colquitt, J.L.; Gospodarevskaya, E.; Loveman, E.; Baxter, L.; Clegg, A.J. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: A systematic review and economic evaluation. Health Technol. Assess. 2009, 13, 215–357.
  2. Biter, L.U.; van Buuren, M.M.A.; Mannaerts, G.H.H.; Apers, J.A.; Dunkelgrün, M.; Vijgen, G.H.E.J. Quality of Life 1 Year After Laparoscopic Sleeve Gastrectomy Versus Laparoscopic Roux-en-Y Gastric Bypass: A Randomized Controlled Trial Focusing on Gastroesophageal Reflux Disease. Obes. Surg. 2017, 27, 2557–2565.
  3. Tai, C.M.; Lee, Y.C.; Wu, M.S.; Chang, C.Y.; Lee, C.T.; Huang, C.K.; Kuo, H.C.; Lin, J.T. The effect of Roux-en-Y gastric bypass on gastroesophageal reflux disease in morbidly obese Chinese patients. Obes. Surg. 2009, 19, 565–570.
  4. Csendes, J.A.; Burgos, L.A.M.; Smok, S.G.; Burdiles, P.P. Efecto del bypass en la esofagitis erosiva en pacientes con obesidad mórbida [Effects of gastric bypass on erosive esophagitis in obese subjects]. Rev. Med. Chil. 2006, 134, 285–890. (In Spanish)
  5. Bacciu, A.; Mercante, G.; Ingegnoli, A.; Ferri, T.; Muzzetto, P.; Leandro, G.; Di Mario, F.; Bacciu, S. Effects of gastroesophageal reflux disease in laryngeal carcinoma. Clin. Otolaryngol. Allied Sci. 2004, 29, 545–548.
  6. Tutuian, R. Obesity and GERD: Pathophysiology and Effect of Bariatric Surgery. Curr. Gastroenterol. Rep. 2011, 13, 205.
  7. Anand, G.; Katz, P.O. Gastroesophageal reflux disease and obesity. Rev. Gastroenterol. Disord. 2008, 8, 233–239.
  8. Mejía-Rivas, M.A.; Herrera-López, A.; Hernández-Calleros, J.; Herrera, M.F.; Valdovinos, M.A. Gastroesophageal Reflux Disease in Morbid Obesity: The Effect of Roux-en-Y Gastric Bypass. Obes. Surg. 2008, 18, 1217–1224.
  9. El-Serag, H.B.; Sweet, S.; Winchester, C.C.; Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2014, 63, 871–880.
  10. Colquitt, J.L.; Pickett, K.; Loveman, E.; Frampton, G.K. Surgery for weight loss in adults. Cochrane Database Syst. Rev. 2014, 8, CD003641.
  11. Angrisani, L.; Santonicola, A.; Iovino, P.; Vitiello, A.; Higa, K.; Himpens, J.; Buchwald, H.; Scopinaro, N. IFSO worldwide survey 2016: Primary, endoluminal, and revisional procedures. Obes. Surg. 2018, 28, 3783–3794.
  12. Butti, F.; Tobler, O.; Allemann, P.; Fournier, P. Gastroesophageal Reflux Disease Following Roux-en-Y Gastric Bypass. J. Laparoendosc. Adv. Surg. Tech. 2020, 30, 875–878.
  13. Raj, P.P.; Bhattacharya, S.; Misra, S.; Kumar, S.S.; Khan, M.J.; Gunasekaran, S.C.; Palanivelu, C. Gastroesophageal reflux-related physiologic changes after sleeve gastrectomy and Roux-en-Y gastric bypass: A prospective comparative study. Surg. Obes. Relat. Dis. 2019, 15, 1261–1269.
  14. Gu, L.; Chen, B.; Du, N.; Fu, R.; Huang, X.; Mao, F.; Khadaroo, P.A.; Zhao, S. Relationship Between Bariatric Surgery and Gastroesophageal Reflux Disease: A Systematic Review and Meta-analysis. Obes. Surg. 2019, 29, 4105–4113.
  15. Borbély, Y.; Kröll, D.; Nett, P.C.; Moreno, P.; Tutuian, R.; Lenglinger, J. Radiologic, endoscopic, and functional patterns in patients with symptomatic gastroesophageal reflux disease after Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis. 2018, 14, 764–768.
  16. Boerlage, T.C.C.; Wolvers, P.J.D.; Bruin, S.C.; Huibregtse, I.L.; Voermans, R.P.; Fockens, P.; Hutten, B.A.; Gerdes, V.E.A. Upper endoscopy after Roux-en-Y gastric bypass: Diagnostic yield and factors associated with relevant findings. Surg. Obes. Relat. Dis. 2020, 16, 868–876.
  17. Huang, C.S.; Forse, R.A.; Jacobson, B.C.; Farraye, F.A. Endoscopic findings and their clinical correlations in patients with symptoms after gastric bypass surgery. Gastrointest. Endosc. 2003, 58, 859–866.
  18. Signorini, F.; Olguín, S.; Viscido, G.; Obeide, L.; Moser, F. Esophagitis evolution after sleeve gastrectomy or gastric bypass in consecutive cases. Surg. Endosc. 2020, 34, 4330–4335.
  19. Dimbezel, V.; Nedelcu, A.; Danan, M.; Carandina, S.; Collet, D.; Gronnier, C.; Nedelcu, M. Endoscopic Findings 5 Years Following Sleeve Gastrectomy. Obes. Surg. 2020, 30, 3847–3851.
  20. Felsenreich, D.M.; Kefurt, R.; Schermann, M.; Beckerhinn, P.; Kristo, I.; Krebs, M.; Prager, G.; Langer, F.B. Reflux, Sleeve Dilation, and Barrett’s Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up. Obes. Surg. 2017, 27, 3092–3101.
  21. Braghetto, I.; Korn, O.; Burgos, A.; Figueroa, M. When should be comverted Laparoscopic Sleeve Gastrectomy to Laparoscopic Roux-en-Y Gastric Bypass due to Gastroesophageal reflux? Arq. Bras. Cir. Dig. 2021, 33, e1553.
  22. Melissas, J.; Daskalakis, M.; Koukouraki, S.; Askoxylakis, I.; Metaxari, M.; Dimitriadis, E.; Stathaki, M.; Papadakis, J.A. Sleeve Gastrectomy—A “Food Limiting” Operation. Obes. Surg. 2008, 18, 1251–1256.
  23. Braghetto, I.; Lanzarini, E.; Korn, O.; Valladares, H.; Molina, J.C.; Henriquez, A. Manometric Changes of the Lower Esophageal Sphincter After Sleeve Gastrectomy in Obese Patients. Obes. Surg. 2010, 20, 357–362.
  24. Himpens, J.; Dapri, G.; Cadière, G.B. A Prospective Randomized Study Between Laparoscopic Gastric Banding and Laparoscopic Isolated Sleeve Gastrectomy: Results after 1 and 3 Years. Obes. Surg. 2006, 16, 1450–1456.
  25. Moulla, Y.; Lyros, O.; Mehdorn, M.; Lange, U.; Hamade, H.; Thieme, R.; Hoffmeister, A.; Feisthammel, J.; Blüher, M.; Jansen-Winkeln, B.; et al. Preoperative Upper-GI Endoscopy Prior to Bariatric Surgery: Essential or Optional? Obes. Surg. 2020, 30, 2076–2084.
  26. Boerlage, T.C.; Westerink, F.; van de Laar, A.W.; Hutten, B.A.; Brandjes, D.P.; Gerdes, V.E. Gastrointestinal symptoms before and after laparoscopic Roux-en-Y gastric bypass: A longitudinal assessment. Surg. Obes. Relat. Dis. 2019, 15, 871–877.
  27. Saarinen, T.; Kettunen, U.; Pietiläinen, K.H.; Juuti, A. Is preoperative gastroscopy necessary before sleeve gastrectomy and Roux-en-Y gastric bypass? Surg. Obes. Relat. Dis. 2018, 14, 757–762.
  28. Gribsholt, S.B.; Pedersen, A.M.; Svensson, E.; Thomsen, R.W.; Richelsen, B. Prevalence of self-reported symptoms after gastric bypass surgery for obesity. JAMA Surg. 2016, 151, 504–511.
  29. Pierik, A.S.; Coblijn, U.K.; de Raaff, C.A.L.; van Veen, R.N.; van Tets, W.F.; van Wagensveld, B.A. Unexplained abdominal pain in morbidly obese patients after bariatric surgery. Surg. Obes. Relat. Dis. 2017, 13, 1743–1751.
  30. Høgestøl, I.K.; Chahal-Kummen, M.; Eribe, I.; Brunborg, C.; Stubhaug, A.; Hewitt, S.; Kristinsson, J.; Mala, T. Chronic abdominal pain and symptoms 5 years after gastric bypass for morbid obesity. Obes. Surg. 2017, 27, 1438–1445.
  31. Bou Daher, H.; Sharara, A.I. Gastroesophageal reflux disease, obesity and laparoscopic sleeve gastrectomy: The burning questions. World J. Gastroenterol. 2019, 25, 4805–4813.
  32. Coblijn, U.K.; Goucham, A.B.; Lagarde, S.M.; Kuiken, S.D.; van Wagensveld, B.A. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: A systematic review. Obes. Surg. 2014, 24, 299–309.
  33. Csendes, A.; Torres, J.; Burgos, A.M. Late marginal ulcers after gastric bypass for morbid obesity. Clinical and endoscopic findings and response to treatment. Obes. Surg. 2011, 21, 1319–1322.
  34. Ahmad, J.; Martin, J.; Ikramuddin, S.; Schauer, P.; Slivka, A. Endoscopic balloon dilation of gastroenteric anastomotic stricture after laparoscopic gastric bypass. Endoscopy 2003, 35, 725–728.
  35. D’Silva, M.; Bhasker, A.G.; Kantharia, N.S.; Lakdawala, M. High-percentage pathological findings in obese patients suggest that Esophago-gastro-duodenoscopy should be made mandatory prior to bariatric surgery. Obes. Surg. 2018, 28, 2753–2759.
  36. Chan, K.; Liu, G.; Miller, L.; Ma, C.; Xu, W.; Schlachta, C.M.; Darling, G. Lack of Correlation Between a Self-Administered Subjective GERD Questionnaire and Pathologic GERD Diagnosed by 24-h Esophageal pH Monitoring. J. Gastrointest. Surg. 2010, 14, 427–436.
  37. Genco, A.; Soricelli, E.; Casella, G.; Maselli, R.; Castagneto-Gissey, L.; Di Lorenzo, N.; Basso, N. Gastroesophageal reflux disease and Barrett’s esophagus after laparoscopic sleeve gastrectomy: A possible, underestimated long-term complication. Surg. Obes. Relat. Dis. 2017, 13, 568–574.
  38. Campos, G.M.; Mazzini, G.S.; Altieri, M.S.; Docimo, S., Jr.; De Maria, E.J.; Rogers, A.M.; Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery. ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. Surg. Obes. Relat. Dis. 2021, 17, 837–847.
  39. Mala, T.; Høgestøl, I. Abdominal Pain After Roux-En-Y Gastric Bypass for Morbid Obesity. Scand. J. Surg. 2018, 107, 277–284.
  40. Braghetto, I.; Csendes, A. Patients having bariatric surgery: Surgical options in morbidly obese patients with Barrett’s esophagus. Obes. Surg. 2016, 26, 1622–1626.
  41. Al Sabah, S.; AlWazzan, A.; AlGhanim, K.; AlAbdulrazzaq, H.A.; Al Haddad, E. Does Laparoscopic Sleeve Gastrectomy lead to Barrett’s esophagus, 5-year esophagogastroduodenoscopy findings: A retrospective cohort study. Ann. Med. Surg. 2021, 62, 446–449.
More
Information
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 405
Revisions: 2 times (View History)
Update Date: 04 Jun 2021
1000/1000